TELA Bio, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M | $29.5M |
| Gross profit | $54.3M | $46.5M | $40.1M | $27.0M | $18.8M |
| Research and development | $9.2M | $8.8M | $9.6M | $8.9M | $6.7M |
| Operating expenses | $88.1M | $88.2M | $84.2M | $66.1M | $48.3M |
| Operating income | -$33.8M | -$34.1M | -$44.1M | -$39.0M | -$29.5M |
| Interest expense | $5.2M | $5.3M | $5.2M | $4.1M | $3.6M |
| Pretax income | -$38.6M | -$38.0M | -$46.7M | -$44.3M | — |
| Income tax expense | $230,000 | -$144,000 | — | — | — |
| Net income | -$38.8M | -$37.8M | -$46.7M | -$44.3M | -$33.3M |
| Balance Sheet | |||||
| Cash and equivalents | $50.8M | $52.7M | $46.7M | $42.0M | $43.9M |
| Current assets | $75.6M | $78.1M | $71.7M | $62.4M | $59.1M |
| Total assets | $81.4M | $86.6M | $78.0M | $67.9M | $62.5M |
| Current liabilities | $18.0M | $15.6M | $17.0M | $12.4M | $10.6M |
| Total liabilities | $75.1M | $58.1M | $59.2M | $53.5M | $42.4M |
| Stockholders' equity | $6.3M | $28.5M | $18.9M | $14.3M | $20.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$28.2M | -$41.6M | -$40.9M | -$40.7M | -$30.4M |
| Depreciation and amortization | $630,000 | $632,000 | $428,000 | $383,000 | $231,000 |
| Stock-based compensation | $3.8M | $4.4M | $5.0M | $4.0M | $3.7M |
| Capital expenditure | $448,000 | $989,000 | $611,000 | $872,000 | $627,000 |
| Free cash flow | -$28.7M | -$42.6M | -$41.5M | -$41.6M | -$31.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 44.8M · Free float 68.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.